A share price of Moderna Inc [MRNA] is currently trading at $38.50, up 7.27%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MRNA shares have gain 11.72% over the last week, with a monthly amount glided 0.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on December 18, 2024, when Argus downgraded its rating to a Hold. On November 19, 2024, Berenberg initiated with a Hold rating and assigned a price target of $42 on the stock. HSBC Securities upgraded its rating to a Buy but stick to its price target of $58 on November 18, 2024. Wolfe Research initiated its recommendation with a Underperform and recommended $40 as its price target on November 15, 2024. Bernstein started tracking with a Mkt Perform rating for this stock on October 17, 2024, and assigned it a price target of $55. In a note dated September 13, 2024, Oppenheimer downgraded an Perform rating on this stock.
Moderna Inc experienced fluctuations in its stock price throughout the past year between $31.94 and $170.47. Currently, Wall Street analysts expect the stock to reach $104.9 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $38.50 at the most recent close of the market. An investor can expect a potential return of 172.47% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Trailing Twelve Months sales for Moderna Inc [NASDAQ:MRNA] were 5.07B which represents 1.69% growth. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.53%, Pretax Profit Margin comes in at -0.46%, and Net Profit Margin reading is -0.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.18 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.97 points at the first support level, and at 33.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.06, and for the 2nd resistance point, it is at 43.62.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Moderna Inc [NASDAQ:MRNA] is 4.39. In addition, the Quick Ratio stands at 4.20 and the Cash Ratio stands at 0.75. Considering the valuation of this stock, the price to sales ratio is 2.92, the price to book ratio is 1.24.
Transactions by insiders
Recent insider trading involved Klinger Shannon Thyme, Chief Legal Officer, that happened on Dec 09 ’24 when 529.0 shares were sold. Officer, Klinger Shannon Thyme completed a deal on Dec 09 ’24 to buy 529.0 shares. Meanwhile, Chief Legal Officer Klinger Shannon Thyme sold 112.0 shares on Dec 03 ’24.
